en · de · es · fr · pt
bench-notes.peptides6088.com › Info › Background And Development History — Deep Dive

Background And Development History — Deep Dive

By Editorial Desk · published 2026-03-31 · last reviewed 2026-04-25 · Info

If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Development History

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Related pages on this site

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Background from the literature

Dalfopristin is a semi-synthetic streptogramin antibiotic analogue of ostreogyrcin A (virginiamycin M, pristinamycin IIA, streptogramin A). The combination quinupristin/dalfopristin (marketed under the trade name Synercid) was brought to the market by Rhone-Poulenc Rorer Pharmaceuticals in 1999. Synercid (weight-to-weight ratio of 30% quinupristin to 70% dalfopristin) is used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

== External links == International Chemical Safety Card 0095 NIOSH Pocket Guide to Chemical Hazards. "#0017". National Institute for Occupational Safety and Health (NIOSH). Institut national de recherche et de sécurité (2004). "Alcool allylique". Fiche toxicologique n° 156 (in French). Paris: INRS. State of Michigan public information on allyl alcohol Occupational exposure guidelines

The majority of toxic chemicals found in e-cigarette vapor are below 1% of the corresponding levels permissible by workplace exposure standards, but the threshold limit values for workplace exposure standards are generally much higher than levels considered satisfactory for outdoor air quality. Some chemicals from exposures to the e-cigarette vapor could be higher than workplace exposure standards. A 2018 PHE report stated that the toxicants found in e-cigarette vapor are less than 5% and the majority are less than 1% in comparison with traditional cigarettes. Although several studies have found lower levels of carcinogens in e-cigarette aerosol compared to smoke emitted by traditional cigarettes, the mainstream and second-hand e-cigarette aerosol has been found to contain at least ten chemicals that are on California's Proposition 65 list of chemicals known to cause cancer, birth defects, or other reproductive harm, including acetaldehyde, benzene, cadmium, formaldehyde, isoprene, lead, nickel, nicotine, N-Nitrosonornicotine, and toluene. Free radicals produced from frequent e-cigarette use is estimated to be greater than compared to air pollution. E-cigarette vapor can contain a range of toxicants, and since they have been be used in methods unintended by the producer such as dripping or mixing liquids, this could result in generating greater levels of toxicants.

Sources: en.wikipedia.org

Further detail

It's possible that hackers have gotten into administrative computer systems of utility companies, but says those aren't linked to the equipment controlling the grid, at least not in developed countries. [Schmidt] has never heard that the grid itself has been hacked. In June 2019, Russia said that its electrical grid has been under cyber-attack by the United States. The New York Times reported that American hackers from the United States Cyber Command planted malware potentially capable of disrupting the Russian electrical grid.

==== Chemical abnormalities ==== Methemoglobinemia is a condition caused by elevated levels of methemoglobin in the blood. Methaemoglobin is a form of hemoglobin that contains the ferric [Fe3+] form of iron, instead of the ferrous [Fe2+] form . Methemoglobin cannot bind oxygen, which means it cannot carry oxygen to tissues. In human blood a trace amount of methemoglobin is normally produced spontaneously; the enzyme methemoglobin reductase is responsible for converting methemoglobin back to hemoglobin. Methemoglobinemia can be hereditary but more commonly occurs as a side effect of certain medications or by abuse of recreational drugs.

DMT is inactive when ingested orally due to metabolism by monoamine oxidase (MAO), and DMT-containing drinks such as ayahuasca have been found to contain monoamine oxidase inhibitors (MAOIs), in particular, harmine and harmaline. Life-threatening lethalities such as serotonin syndrome (SS) may occur when MAOIs are combined with certain serotonergic medications such as selective serotonin reuptake inhibitor (SSRI) antidepressants. Serotonin syndrome has also been reported with tricyclic antidepressants (TCAs), certain opioids, certain analgesics, and antimigraine drugs; it is advised to exercise caution when an individual has used dextromethorphan (DXM), MDMA, ginseng, or St. John's wort recently. Chronic use of SSRIs, TCAs, and MAOIs diminish subjective effects of psychedelics due to presumed serotonin 5-HT2A receptors downregulation and/or desensitization secondary to elevated serotonin levels. However, a clinical study of people with depression found that SSRIs did not diminish the effects of DMT and instead resulted in greater mystical experience, emotional breakthrough, and ego dissolution scores with DMT than in people with depression not on antidepressants. This was in contrast to previous research finding that SSRIs diminished the effects of serotonergic psychedelics. The interaction between psychedelics and antipsychotics and anticonvulsants are not well documented; however, reports reveal that co-use of psychedelics with mood stabilizers such as lithium may provoke seizure and dissociative effects in individuals with bipolar disorder.

Narrated by Henrietta Bess, produced by Nicholas Kent, directed by Peter Webber 19 July What Shall We Do with the Moon?, shown thirty years after the 1969 Moon landing; about colonization of the Moon; Greg Bennett (writer); the Apollo 17 mission, in December 1972; Alan Binder, who worked on the January 1998 Lunar Prospector, which discovered water on the Moon; Jim Benson and his SpaceDev at Poway, California; the Thunderbird proposal of Starchaser Industries; the Nomad rover, developed by Carnegie Mellon University in Pittsburgh; chemist Nigel Packham of NASA; physicist David Criswell, and solar power on the Moon. Narrated by Scottish actress Daniela Nardini, produced by Katrina Phillips, directed by Chris Durlacher, made by Wall to Wall Television. Shown on the Discovery Science (European TV channel) 6 September Frozen Hearts, up to 50% of people on a heart-lung machine have some form of brain deterioration, and for one in five, the deterioration is permanent Alan Egar had heart surgery, but he had memory difficulties after the operation; he found difficulty finishing sentences; in the US four-year-old Samantha Summers is put on a heart-lung machine at Boston Children's Hospital; David Eckmann, later the Horatio C.

Sources: en.wikipedia.org

Supporting material

The Mumbai-Nagpur Expressway, or Samruddhi Mahamarg (officially known as Hindu Hruidaysamrat Balasaheb Thackeray Maharashtra Samruddhi Mahamarg) and Maharashtra Expressway-2 (ME-2), is an existing operational 6-lane wide (expandable to 8), 701-km long access-controlled expressway in the Maharashtra state of India, connecting the Maharashtra's two capital cities, Mumbai in the Marathwada region in the west and Nagpur in the Vidarbha region in the east. By reducing Nagpur-Mumbai travel time to 8 hours, the expressway has boosted the economic development by providing the enhanced connectivity. It is the second expressway in the state of Maharashtra after the Mumbai–Pune Expressway, and the longest within the state.

=== Indonesia === The Indonesian National Armed Forces (TNI) has introduced the "TNI ration" (Indonesian: Ransum TNI) in the mid-1970s in order to standardize nutrition for soldiers in field. There are three types of ration and each daily ration consist of three menus (breakfast, lunch, and dinner), a pack of supplementary drinks, providing approximately 2,700 kcal (11,000 kJ) in total. The main course are usually meat-based meals (fish, beef, chicken, etc.) with cooked rice. The supplementary drinks are instant coffee, powdered fruit juice or vitamin supply, tea bags and powdered milk. The rations should be heated for 10–15 minutes with the included portable stove and solid fuel tablets (for canned meals), or by submerging in boiling water (for meals packed in retort pouches). All products are made in Indonesia and manufactured according to Indonesian military standard.

== In various fields == As a central goal of many individual and societal endeavors, well-being is relevant to many fields of inquiry. Grouped under the umbrella term science of well-being, some disciplines investigate the nature and components of well-being directly, while others study its causes, effects, or correlates in specific domains of life. A central motivation of academic inquiry is the belief that well-being can be improved through appropriate measures. Some of these measures focus on individual lifestyle changes. Others take the form of societal interventions to alter how economic, medical, educational, workplace, and political institutions function.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

Network